VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 15 2025
0mins
Should l Buy VNRX?
Source: Newsfilter
Earnings Conference Call Overview: VolitionRx Limited held its Q2 2025 earnings conference call on August 15, 2025, featuring key company executives discussing financial performance and future outlook.
Forward-Looking Statements Disclaimer: The call included a reminder about forward-looking statements that involve risks and uncertainties, with actual results potentially differing from those projected due to various factors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNRX
Wall Street analysts forecast VNRX stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.163
Low
1.50
Averages
2.25
High
3.00
Current: 0.163
Low
1.50
Averages
2.25
High
3.00
About VNRX
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VolitionRx Launches rNuQ Webshop to Expand Product Line
- Product Line Expansion: VolitionRx has launched the rNuQ webshop, offering a variety of reliable recombinant nucleosomes developed over 10 years, aimed at meeting the needs of nearly 100 global clients and accelerating disease research and drug development.
- Quality Control Advantage: All recombinant nucleosomes are manufactured in an ISO 13485 certified facility, ensuring exceptional reproducibility and quality control, simplifying handling while preserving structural integrity and enhancing experimental performance.
- Market Growth Potential: In 2025, Nu.Q® Discover achieved an 86% revenue growth, with a similar trajectory anticipated for 2026, indicating strong momentum in the company's commercialization efforts.
- Future Development Direction: VolitionRx is in discussions with several pharmaceutical companies for the bespoke development of assays, planning to expand its offerings to other biospecimens, further enhancing its market competitiveness in the biomedical field.
See More
VolitionRX Reports 133% Revenue Growth in Q4 2025
- Significant Revenue Growth: VolitionRX achieved a remarkable 133% year-on-year growth in Q4 2025, with total revenue reaching $1.7 million for the year, a 40% increase over 2024, indicating strong demand and potential market expansion in cancer detection.
- Operating Expenses Reduced: The company successfully cut operating expenses by $4.8 million, a 17% decrease compared to 2024, demonstrating effective cost control measures that enhance overall financial health.
- Cash Flow Warning: Despite revenue growth, net cash used in operating activities was $19.7 million in 2025, down from $25.9 million in 2024; however, cash and cash equivalents were only approximately $1.1 million, highlighting the urgent need for additional funding to sustain operations.
- Strategic Partnership Progress: VolitionRX signed significant agreements with Werfen and Hologic to commercialize its Nu.Q platform, marking a crucial step in the company's strategic positioning within the clinical diagnostics market, which is expected to drive future revenue growth.
See More
VolitionRx Q4 2025 Earnings Call Highlights
- New Product Orders: In Q4 2025, VolitionRx secured its first order for Nu.Q Cancer assays for clinical certification, marking a significant advancement towards routine clinical use in lung cancer, which is expected to drive future market demand and revenue growth.
- Significant Revenue Growth: The company reported full-year revenue of $1.7 million for 2025, reflecting a 40% increase, while operating expenses decreased by 17%, indicating substantial progress in cost control that will enhance profitability.
- Strategic Partnership Agreements: VolitionRx initiated its human licensing strategy by signing two agreements with Hologic and Werfen, which will help expand market reach and strengthen collaborations with industry leaders.
- Future Outlook: Although management did not provide revenue guidance for 2026, they anticipate continuing to pursue multiple licensing agreements and aim to further reduce cash operating expenses by 25%-30%, enhancing financial flexibility and market competitiveness.
See More
VolitionRX Reports 40% Revenue Growth in FY
- Fiscal Year Revenue Growth: VolitionRX reported FY revenue of $1.7 million, representing a 40% increase over the previous year, indicating the company's sustained growth potential in the competitive biotechnology sector.
- Reduced Net Loss: The company's net loss decreased by 14% compared to 2024, suggesting effective cost control measures that improve financial health and bolster investor confidence.
- Improved Cash Utilization: Cash used in operating activities was $19.7 million, down 24% year-over-year, reflecting optimization in resource allocation and operational efficiency, potentially providing more flexibility for future investments.
- Non-Dilutive Funding Secured: VolitionRX secured €2 million in non-dilutive funding from Belgian agencies, which will support its R&D and market expansion efforts, further solidifying its position in the industry.
See More
VolitionRx Secures €2 Million Non-Dilutive Financing
- Funding for Development: VolitionRx secured €2 million in non-dilutive financing from Namur Invest and Wallonie Entreprendre, which will be used to support the development of its Nu.Q product portfolio, particularly the regulatory transition work for Nu.Q NETs, potentially accelerating the product's market entry.
- Strategic Financing Plan: This financing is part of the company's strategy to secure non-dilutive funding for ongoing development, with total non-dilutive funding to date exceeding $25 million, enhancing the company's financial stability and R&D capabilities.
- Improving Access in Low-Income Countries: The funds will be directed towards the development of a lateral flow product aimed at improving access to medical products in low-income countries, reflecting the company's commitment to global health equity while laying the groundwork for future market expansion.
- Stock Price Reaction: Following the financing announcement, VolitionRx's stock price rose by 0.05% in pre-market trading to $0.1901, indicating a positive market sentiment regarding the company's financing and growth prospects.
See More
Nu.Q® Biomarkers Clinical Study Published in Shock Journal
- Clinical Study Findings: VolitionRx's research reveals that nucleosome levels, specifically Nu.Q® H3.1 and H3R8 Citrulline, are significantly elevated in 674 trauma patients post-injury, particularly in those who develop Venous Thromboembolism (VTE), indicating the potential clinical utility of these biomarkers in trauma care.
- Importance of Biomarkers: The study underscores the clinical challenge of identifying reliable biomarkers in trauma patients, especially in emergency and surgical settings, suggesting that these findings could support early risk identification and targeted preventive strategies, ultimately improving patient outcomes.
- Commercialization Prospects: The peer-reviewed publication with the Mayo Clinic research team strongly supports Volition's efforts to commercialize its Nu.Q® NETs product, indicating promising market opportunities in the trauma care sector.
- Future Research Directions: Researchers indicate that Nu.Q® NETs may assist clinicians and researchers in anticipating disease, guiding treatment decisions, and monitoring patients, showcasing broad application potential across acute and chronic conditions.
See More
VolitionRx Launches rNuQ Webshop to Expand Product Line
- Product Line Expansion: VolitionRx has launched the rNuQ webshop, offering a variety of reliable recombinant nucleosomes developed over 10 years, aimed at meeting the needs of nearly 100 global clients and accelerating disease research and drug development.
- Quality Control Advantage: All recombinant nucleosomes are manufactured in an ISO 13485 certified facility, ensuring exceptional reproducibility and quality control, simplifying handling while preserving structural integrity and enhancing experimental performance.
- Market Growth Potential: In 2025, Nu.Q® Discover achieved an 86% revenue growth, with a similar trajectory anticipated for 2026, indicating strong momentum in the company's commercialization efforts.
- Future Development Direction: VolitionRx is in discussions with several pharmaceutical companies for the bespoke development of assays, planning to expand its offerings to other biospecimens, further enhancing its market competitiveness in the biomedical field.
See More
VolitionRX Reports 133% Revenue Growth in Q4 2025
- Significant Revenue Growth: VolitionRX achieved a remarkable 133% year-on-year growth in Q4 2025, with total revenue reaching $1.7 million for the year, a 40% increase over 2024, indicating strong demand and potential market expansion in cancer detection.
- Operating Expenses Reduced: The company successfully cut operating expenses by $4.8 million, a 17% decrease compared to 2024, demonstrating effective cost control measures that enhance overall financial health.
- Cash Flow Warning: Despite revenue growth, net cash used in operating activities was $19.7 million in 2025, down from $25.9 million in 2024; however, cash and cash equivalents were only approximately $1.1 million, highlighting the urgent need for additional funding to sustain operations.
- Strategic Partnership Progress: VolitionRX signed significant agreements with Werfen and Hologic to commercialize its Nu.Q platform, marking a crucial step in the company's strategic positioning within the clinical diagnostics market, which is expected to drive future revenue growth.
See More
VolitionRx Q4 2025 Earnings Call Highlights
- New Product Orders: In Q4 2025, VolitionRx secured its first order for Nu.Q Cancer assays for clinical certification, marking a significant advancement towards routine clinical use in lung cancer, which is expected to drive future market demand and revenue growth.
- Significant Revenue Growth: The company reported full-year revenue of $1.7 million for 2025, reflecting a 40% increase, while operating expenses decreased by 17%, indicating substantial progress in cost control that will enhance profitability.
- Strategic Partnership Agreements: VolitionRx initiated its human licensing strategy by signing two agreements with Hologic and Werfen, which will help expand market reach and strengthen collaborations with industry leaders.
- Future Outlook: Although management did not provide revenue guidance for 2026, they anticipate continuing to pursue multiple licensing agreements and aim to further reduce cash operating expenses by 25%-30%, enhancing financial flexibility and market competitiveness.
See More
VolitionRX Reports 40% Revenue Growth in FY
- Fiscal Year Revenue Growth: VolitionRX reported FY revenue of $1.7 million, representing a 40% increase over the previous year, indicating the company's sustained growth potential in the competitive biotechnology sector.
- Reduced Net Loss: The company's net loss decreased by 14% compared to 2024, suggesting effective cost control measures that improve financial health and bolster investor confidence.
- Improved Cash Utilization: Cash used in operating activities was $19.7 million, down 24% year-over-year, reflecting optimization in resource allocation and operational efficiency, potentially providing more flexibility for future investments.
- Non-Dilutive Funding Secured: VolitionRX secured €2 million in non-dilutive funding from Belgian agencies, which will support its R&D and market expansion efforts, further solidifying its position in the industry.
See More
VolitionRx Secures €2 Million Non-Dilutive Financing
- Funding for Development: VolitionRx secured €2 million in non-dilutive financing from Namur Invest and Wallonie Entreprendre, which will be used to support the development of its Nu.Q product portfolio, particularly the regulatory transition work for Nu.Q NETs, potentially accelerating the product's market entry.
- Strategic Financing Plan: This financing is part of the company's strategy to secure non-dilutive funding for ongoing development, with total non-dilutive funding to date exceeding $25 million, enhancing the company's financial stability and R&D capabilities.
- Improving Access in Low-Income Countries: The funds will be directed towards the development of a lateral flow product aimed at improving access to medical products in low-income countries, reflecting the company's commitment to global health equity while laying the groundwork for future market expansion.
- Stock Price Reaction: Following the financing announcement, VolitionRx's stock price rose by 0.05% in pre-market trading to $0.1901, indicating a positive market sentiment regarding the company's financing and growth prospects.
See More
Nu.Q® Biomarkers Clinical Study Published in Shock Journal
- Clinical Study Findings: VolitionRx's research reveals that nucleosome levels, specifically Nu.Q® H3.1 and H3R8 Citrulline, are significantly elevated in 674 trauma patients post-injury, particularly in those who develop Venous Thromboembolism (VTE), indicating the potential clinical utility of these biomarkers in trauma care.
- Importance of Biomarkers: The study underscores the clinical challenge of identifying reliable biomarkers in trauma patients, especially in emergency and surgical settings, suggesting that these findings could support early risk identification and targeted preventive strategies, ultimately improving patient outcomes.
- Commercialization Prospects: The peer-reviewed publication with the Mayo Clinic research team strongly supports Volition's efforts to commercialize its Nu.Q® NETs product, indicating promising market opportunities in the trauma care sector.
- Future Research Directions: Researchers indicate that Nu.Q® NETs may assist clinicians and researchers in anticipating disease, guiding treatment decisions, and monitoring patients, showcasing broad application potential across acute and chronic conditions.
See More
